Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2007 1
2008 3
2009 1
2010 2
2011 1
2012 3
2013 2
2014 2
2015 3
2016 3
2017 6
2018 2
2019 4
2020 5
2021 8
2022 8
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for naoki yamashita
Search for Naoaki Yamashita instead (2 results)
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: yamashita n. Aliment Pharmacol Ther. 2022 Aug;56(4):713-722. doi: 10.1111/apt.17107. Epub 2022 Jun 23. Aliment Pharmacol Ther. 2022. PMID: 35735794 Free PMC article.
Regorafenib could cause sinusoidal obstruction syndrome.
Takahashi M, Harada S, Suzuki H, Yamashita N, Orita H, Kato M, Kotoh K. Takahashi M, et al. Among authors: yamashita n. J Gastrointest Oncol. 2016 Jun;7(3):E41-4. doi: 10.21037/jgo.2015.11.01. J Gastrointest Oncol. 2016. PMID: 27284487 Free PMC article.
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Sugimoto R, Motomura K, Ooho A, Aratake Y, Ueda A, Senju T, Tanaka Y, Yada M, Tanaka K, Kuwano A, Morita Y, Nagasawa S, Ooe M, Mutsuki T, Yoshimoto T, Yamashita N, Nakashima M, Hioki T, Koyanagi T, Higuchi N, Nakamura T, Harada S, Tanaka M, Tada S, Satoh T, Uchimura K, Kuniyoshi M, Nakamuta M, Kohjima M; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: yamashita n. Intern Med. 2022;61(21):3157-3164. doi: 10.2169/internalmedicine.9237-21. Epub 2022 Nov 1. Intern Med. 2022. PMID: 36328582 Free PMC article.
52 results